FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1154-1155 October 27, 1994 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The introduction of cyclosporine as an immunosuppressive agent improved the results of all types of organ transplantations¹ and allowed liver transplantation to become the treatment of choice for many patients with end-stage liver disease.² The rejection seen after liver transplantation tends to be less severe than that occurring after heart or kidney transplantation. Although acute rejection of the liver is common, it can usually be reversed with high doses of corticosteroids. Chronic rejection that is resistant to treatment with corticosteroids and antilymphocyte antibodies occurs in approximately 10 percent of cases. The liver is the main site of metabolism of cyclosporine. . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Xia, S., Guo, Z., Xu, X., Yi, H., Wang, Q., Cao, X. (2008). Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance. Blood 112: 3175-3185 [Abstract] [Full Text]